Kelly Financial Services LLC Cuts Position in Johnson & Johnson (NYSE:JNJ)

Kelly Financial Services LLC decreased its holdings in Johnson & Johnson (NYSE:JNJ) by 2.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,108 shares of the company’s stock after selling 94 shares during the quarter. Kelly Financial Services LLC’s holdings in Johnson & Johnson were worth $449,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Itau Unibanco Holding S.A. increased its position in shares of Johnson & Johnson by 7.5% in the second quarter. Itau Unibanco Holding S.A. now owns 3,018 shares of the company’s stock valued at $441,000 after buying an additional 211 shares in the last quarter. Harmony Asset Management LLC increased its position in shares of Johnson & Johnson by 22.2% in the second quarter. Harmony Asset Management LLC now owns 19,211 shares of the company’s stock valued at $2,808,000 after buying an additional 3,490 shares in the last quarter. Magnetar Financial LLC purchased a new position in shares of Johnson & Johnson in the second quarter valued at $80,751,000. Evergreen Capital Management LLC boosted its stake in shares of Johnson & Johnson by 3.8% during the second quarter. Evergreen Capital Management LLC now owns 110,063 shares of the company’s stock valued at $16,087,000 after acquiring an additional 4,009 shares during the last quarter. Finally, Providence Capital Advisors LLC boosted its stake in shares of Johnson & Johnson by 12.4% during the second quarter. Providence Capital Advisors LLC now owns 40,909 shares of the company’s stock valued at $5,979,000 after acquiring an additional 4,500 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $147.03 on Tuesday. The firm has a market capitalization of $353.99 billion, a P/E ratio of 21.28, a P/E/G ratio of 2.30 and a beta of 0.51. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $168.85. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The business’s 50-day simple moving average is $148.51 and its 200-day simple moving average is $156.10.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.37%. Johnson & Johnson’s payout ratio is currently 71.78%.

Insider Activity at Johnson & Johnson

In related news, Director Mark A. Weinberger bought 1,000 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the acquisition, the director now owns 1,000 shares in the company, valued at $147,220. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Morgan Stanley increased their price objective on Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Wells Fargo & Company increased their price objective on Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. Royal Bank of Canada increased their price objective on Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research note on Wednesday, October 16th. Finally, Citigroup decreased their price target on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. Seven analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $174.29.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.